MA34099B1 - Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose - Google Patents

Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose

Info

Publication number
MA34099B1
MA34099B1 MA35266A MA35266A MA34099B1 MA 34099 B1 MA34099 B1 MA 34099B1 MA 35266 A MA35266 A MA 35266A MA 35266 A MA35266 A MA 35266A MA 34099 B1 MA34099 B1 MA 34099B1
Authority
MA
Morocco
Prior art keywords
endometriosis
treatment
ovarian
aromatase
gestagens
Prior art date
Application number
MA35266A
Other languages
Arabic (ar)
English (en)
Inventor
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Harri Jukarainen
Henriikka Korolainen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34099(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34099B1 publication Critical patent/MA34099B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne le traitement de l'endométriose et a pour objet la production d'une forme galénique parentérale (système d'administration) pour la libération contrôlée d'un inhibiteur de l'aromatase (ai) à une vitesse de libération quotidienne n'induisant aucune stimulation des ovaires par rétroaction négative de l'axe hypophyse-ovaires (qui provoquerait une sécrétion des gonadotropines et une stimulation de la croissance des follicules ovariens), et d'un gestagène à une vitesse de libération quotidienne inférieure à la dose inhibant l'ovulation qui fournit un effet contraceptif sur la base d'effets locaux (par exemple, diminution et épaississement de la glaire cervicale en vue d'empêcher la progression des spermatozoïdes, effets sur l'endomètre et sur la motilité des trompes, dans le but d'empêcher l'implantation et le transport des ovules).
MA35266A 2010-03-31 2011-03-28 Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose MA34099B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
PCT/EP2011/054737 WO2011120925A1 (fr) 2010-03-31 2011-03-28 Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose

Publications (1)

Publication Number Publication Date
MA34099B1 true MA34099B1 (fr) 2013-03-05

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35266A MA34099B1 (fr) 2010-03-31 2011-03-28 Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose

Country Status (41)

Country Link
US (2) US20130131027A1 (fr)
EP (1) EP2552404B1 (fr)
JP (2) JP6012048B2 (fr)
KR (1) KR20130010047A (fr)
CN (1) CN103002873B (fr)
AR (1) AR080861A1 (fr)
AU (1) AU2011234587B2 (fr)
BR (1) BR112012024739A2 (fr)
CA (1) CA2794790A1 (fr)
CL (1) CL2012002722A1 (fr)
CO (1) CO6630125A2 (fr)
CR (1) CR20120493A (fr)
CU (1) CU20120145A7 (fr)
CY (1) CY1116187T1 (fr)
DE (1) DE102010003494A1 (fr)
DK (1) DK2552404T3 (fr)
DO (1) DOP2012000255A (fr)
EA (1) EA025582B1 (fr)
EC (1) ECSP12012176A (fr)
ES (1) ES2533101T3 (fr)
GT (1) GT201200267A (fr)
HR (1) HRP20150294T1 (fr)
IL (1) IL222056A (fr)
MA (1) MA34099B1 (fr)
ME (1) ME02159B (fr)
MX (1) MX2012011329A (fr)
MY (1) MY160353A (fr)
NZ (1) NZ602698A (fr)
PE (1) PE20130524A1 (fr)
PH (1) PH12012501944A1 (fr)
PL (1) PL2552404T3 (fr)
PT (1) PT2552404E (fr)
RS (1) RS53876B1 (fr)
SG (1) SG184111A1 (fr)
SI (1) SI2552404T1 (fr)
TN (1) TN2012000468A1 (fr)
TW (2) TW201632184A (fr)
UA (1) UA109655C2 (fr)
UY (1) UY33303A (fr)
WO (1) WO2011120925A1 (fr)
ZA (1) ZA201206869B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
JP2018515796A (ja) * 2015-05-27 2018-06-14 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX381469B (es) * 2015-12-21 2025-03-12 Bayer Oy Metodo para fabricar un dispositivo para la administracion de farmacos.
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
CA3251695A1 (fr) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Dispositif d’anneau intravaginal pour l’administration d’un inhibiteur d’aromatase
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572L (fi) * 2000-03-13 2001-09-14 Leiras Oy Implantaattien asettamiseen tarkoitettu laite
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (fr) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Methode de traitement des troubles gynecologiques benins et trousse pharmaceutique destinee a etre utilisee dans ladite methode
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
CA2794790A1 (fr) 2011-10-06
CY1116187T1 (el) 2017-02-08
EP2552404A1 (fr) 2013-02-06
JP2013523683A (ja) 2013-06-17
DK2552404T3 (en) 2015-03-30
DOP2012000255A (es) 2013-04-30
EA025582B1 (ru) 2017-01-30
UY33303A (es) 2011-10-31
CR20120493A (es) 2012-11-22
CN103002873B (zh) 2015-02-18
ES2533101T3 (es) 2015-04-07
JP6012048B2 (ja) 2016-10-25
US20150359802A1 (en) 2015-12-17
ZA201206869B (en) 2016-01-27
ME02159B (me) 2015-10-20
DE102010003494A1 (de) 2011-10-06
GT201200267A (es) 2014-06-04
AR080861A1 (es) 2012-05-16
AU2011234587A1 (en) 2012-10-25
RS53876B1 (sr) 2015-08-31
HRP20150294T1 (hr) 2015-06-19
MY160353A (en) 2017-02-28
SG184111A1 (en) 2012-10-30
CL2012002722A1 (es) 2013-01-18
CN103002873A (zh) 2013-03-27
HK1179531A1 (en) 2013-10-04
WO2011120925A1 (fr) 2011-10-06
PH12012501944A1 (en) 2017-01-06
NZ602698A (en) 2014-08-29
PT2552404E (pt) 2015-03-30
PE20130524A1 (es) 2013-04-26
IL222056A (en) 2016-03-31
BR112012024739A2 (pt) 2016-06-07
SI2552404T1 (sl) 2015-04-30
TW201632184A (zh) 2016-09-16
CU20120145A7 (es) 2013-05-31
US20130131027A1 (en) 2013-05-23
EA201201358A1 (ru) 2013-04-30
TW201201799A (en) 2012-01-16
JP2016164200A (ja) 2016-09-08
CO6630125A2 (es) 2013-03-01
UA109655C2 (uk) 2015-09-25
ECSP12012176A (es) 2012-10-30
PL2552404T3 (pl) 2015-05-29
TN2012000468A1 (en) 2014-01-30
EP2552404B1 (fr) 2015-01-21
KR20130010047A (ko) 2013-01-24
AU2011234587B2 (en) 2015-07-09
MX2012011329A (es) 2012-11-30
TWI576107B (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
MA34099B1 (fr) Forme galénique parentérale libérant des inhibiteurs de l'aromatase et des gestagènes, pour le traitement de l'endométriose
JF et al. Regulation of follicle waves to maximize fertility in cattle
Vilariño et al. Ovarian responses and pregnancy rate with previously used intravaginal progesterone releasing devices for fixed-time artificial insemination in sheep
Bridges et al. Decreasing the interval between GnRH and PGF2α from 7 to 5 days and lengthening proestrus increases timed-AI pregnancy rates in beef cows
BR112019006227A2 (pt) métodos de tratamento de leiomioma uterino e endometriose
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
Ungerfeld et al. Estrus response to the ram effect in Corriedale ewes primed with medroxyprogesterone during the breeding season
Bonato et al. Effects of d-cloprostenol administrations with 7.5 and 11.5-day intervals between administrations on pregnancy rates after artificial insemination in estrous cyclic dairy goats
Romano et al. A note on the effect of continuous ram presence on estrus onset, estrus duration and ovulation time in estrus synchronized ewes
MX363979B (es) Forma de dosificacion de un antagonista del receptor de progesterona.
Waldron et al. Effect of concomitant injection of prostaglandin and PMSG on pregnancy rate and prolificacy of artificially inseminated Spanish goats synchronized with controlled internal drug release devices
Elassar et al. Estradiol and antagonist pretreatment prior to microdose leuprolide in in vitro fertilization. Does it improve IVF outcomes in poor responders as compared to oral contraceptive pill?
TH133904A (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
Day et al. Controlling the dominant follicle in beef cattle to improve estrous synchronization and early embryonic development
Khalilzadeh et al. Uses of CIDR, FSH and GnRH for treatment of anoestrus syndrome in dairy cow
Kundulkar et al. Absence of potential benefit of progesterone priming during ovsynch protocol in postpartum anestrous buffalo near the end of breeding season
Valencia et al. Exposure to the male does not exert a luteolytic effect in cyclic goats
Youssef et al. GnRH antagonist for pituitary desensitization in IVF: Is it a time for a change of practice?
Endometriosis et al. ONEXAMINATION QUIZ
UA145642U (uk) Спосіб профілактики перинатальних ускладнень при невиношуванні в ранні терміни вагітності
Dong-Soo et al. Timed Artificial Insemination or Embryo Transfer using CIDR, Estradiol Benzoate and Prostaglandin F₂α for the Rebreeding of Korean Native Donor Cattle
UA37806U (ru) Способ лечения эрозии шнйки матки, вызванной вирусом папилломы человека
HUANG et al. Different Pretreatments before Application of GnRH Antagonist Protocol in Controlled Ovarian Hyperstimulation
Bhat et al. Effect of human chorionic gonadotropin on post-ovulatory mid-luteal profile and subsequent pregnancy rate in anestrus buffalo using two synchronization regimes
Stevenson et al. Estrus Synchronization: Cattle